Perfil
David E.
Moller is currently an Independent Non-Executive Director at Eccogene, Inc. since 2024, an Independent Non-Executive Director at Variant Bio, Inc. starting in 2025, and a Venture Partner at Third Rock Ventures LLC starting in 2025.
Former positions include Vice President-Endocrine & Cardiovascular Research at Eli Lilly & Co., Vice President-Metabolic Disorders at Merck & Co., Inc., Chief Scientific Officer & Executive VP at Poxel SA, Chief Scientific Officer at Sigilon Therapeutics, Inc. from 2018 to 2020, Assistant Professor at Harvard Medical School, and Vice President at Merck Research Laboratories Massachusetts LLC.
Education includes an undergraduate degree from Brown University conferred in 1978 and a doctorate from The University of Cincinnati College of Medicine conferred in 1983.
Cargos activos de David Moller
| Empresas | Cargo | Inicio |
|---|---|---|
Variant Bio, Inc.
Variant Bio, Inc. BiotechnologyHealth Technology Develops therapeutics for human generic diversity | Director/Miembro de la Junta | 01/06/2025 |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Inversor de Capital Privado | 01/06/2025 |
Antiguos cargos conocidos de David Moller.
| Empresas | Cargo | Fin |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2020 |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Corporate Officer/Principal | - |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formación de David Moller.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 10 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Poxel SA
Poxel SA Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases | Health Technology |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
The University of Cincinnati College of Medicine
The University of Cincinnati College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics and functional cures for patients with chronic diseases | Health Technology |
Variant Bio, Inc.
Variant Bio, Inc. BiotechnologyHealth Technology Develops therapeutics for human generic diversity | Health Technology |
- Bolsa de valores
- Insiders
- David Moller
















